Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/anthralin-corticosteroid-combination-therapy-in-the-treatment-of-dya7no0g93
- Publisher
- American Medical Association
- Copyright
- Copyright © 1988 American Medical Association. All Rights Reserved.
- ISSN
- 0003-987X
- eISSN
- 1538-3652
- DOI
- 10.1001/archderm.1988.01670040050021
- Publisher site
- See Article on Publisher Site
Abstract
Abstract † A prospective randomized trial of anthralin in Lassar's paste compared with anthralin in 0.0125% clobetasol propionate in the treatment of chronic plaque psoriasis was undertaken. The psoriatic skin of patients treated with the corticosteroid-anthralin combination cleared significantly more quickly than those treated with anthralin alone, with a mean time to clearance of 14.9 days compared with 18.5 days, and with lower concentrations of anthralin. No significant difference was found in the rate of relapse of the two treatment groups, with relapse occurring in over 80% of patients within one year. Anthralin in 0.0125% clobetasol propionate was found to be an effective agent in the treatment of chronic plaque psoriasis, and one that was cosmetically acceptable to patients and nursing staff. An important disadvantage, however, was the development of a staphylococcal folliculitis in four of the 35 patients in which it was used. Because of this, anthralin in Lassar's paste remains our standard inpatient therapy, although the ease of use and cosmetic acceptability of anthralin in clobetasol propionate make it a useful remedy for outpatient use. (Arch Dermatol 1988;124:548-550) References 1. Ingram JT: The approach to psoriasis Br Med J 1953;2:591-594. 2. Vella Briffa D, Greaves MW, Warin A, et al: Relapse rate and long-term management of plaque psoriasis after treatment with photochemotherapy and dithranol . Br Med J 1981;282:937-940.Crossref 3. Williams DI, Wilkinson DS, Overton J, et al: Betamethasone 17-valerate, a new topical corticosteroid . Lancet 1964;1:1177-1179.Crossref 4. Schmoll M, Henseler T, Christophers E: Evaluation of PUVA, topical corticosteroids and the combination of both in treatment of psoriasis . Br J Dermatol 1978;99:693-702.Crossref 5. Boxley JP, Dawber RPR, Summerly R: Generalised pustular psoriasis on withdrawal of clobetasol propionate ointment . Br Med J 1975;2:255-256.Crossref 6. Cornell RC, Stoughton RB: Correlation of the vasoconstriction assay and clinical activity in psoriasis . Arch Dermatol 1985;121:63-67.Crossref 7. Wilson L: The clinical assessment of topical corticosteroid activity . Br J Dermatol 1976;94( (suppl 12) ):33-42.Crossref 8. Sparkes CG, Wilson L: The clinical evaluation of a new topical corticosteroid, clobetasol propionate . Br J Dermatol 1974; 90:197-203.Crossref 9. Clement M, Hehir M, Phillips H, et al: The effects on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis . Br J Dermatol 1983;109:327-335.Crossref 10. Farber EM, Harris DR: Hospital treatment of psoriasis . Arch Dermatol 1970;101:381-396.Crossref 11. Seville RH: Relapse of psoriasis worsened by adding steroids to a dithranol regimen . Br J Dermatol 1976;95:643-646.Crossref 12. Munro DD, Pringle WM: Psoriasis: Its response to dithranol and clobetasol propionate: A comparative study , in Wilson L, Marks R (eds): Mechanisms of Topical Corticosteroid Activity . London, Churchill Livingstone Inc, 1976, pp 54-60.
Journal
Archives of Dermatology – American Medical Association
Published: Apr 1, 1988